Edgewood is a clinical-stage biotech advancing BTX-A51, a promising multi-kinase inhibitor, in AML and targeted solid tumor populations.

Forma focused on rare hematology and targeted oncology with a field-leading PKR activator for sickle cell disease. Acquired by Novo Nordisk in Oct 2022.

X-Biotix is a biotech company specializing in the development of novel small molecule antibiotic scaffolds for multi-drug resistant (MDR) gram-negative pathogens to address the urgent and growing global threat of antibiotic resistance.

Over the past century, antibiotics, changes in nutrition, and other environmental factors have dramatically altered the shape of the human microbiome. These microbial ecologies residing in and on the human body are now understood to be vital to our health. Seres is pioneering a new approach to fundamentally restore and maintain healthy microbiomes. In it's 6+ year history, Seres has advanced 2 products to late-stage clinical trials in C. diff infection and IBD, and is initiating a ground breaking collaboration with the Parker Institute and MD Anderson to examine the role of the microbiome in checkpoint inhibitor therapy.

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996 and operational in 25 countries, IAVI and its network of collaborators research and develop vaccine candidates. As chief operating officer, I am responsible for leading the senior management team, overseeing IAVI’s U.S. and global operations and working closely with IAVI’s CEO to drive the organization’s strategy for ensuring the development of an AIDS vaccine

Consultant working to develop strategy to bring biotech companies into global health field

Anza Therapeutics’ mission is to develop therapeutic and prophylactic vaccines based on its proprietary vaccine platforms. Company is a biotech start-up funded by venture firms Versant Ventures, Kleiner Perkins and Sofinnova Ventures.

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.

Development-stage, venture-funded company commercializing proprietary cell selection products for engineering of hematopoietic stem cells. Acquired in 2001 by BioTransplant, Inc.